



The claimed invention is:

1. A compound selected from the group consisting of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII) and formula (VIII):


5




I




II




III




IV




V



VI



VII



VIII

wherein:

A is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkylaryl, and alkylheteroaryl;


10

W is selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl;

E is selected from the group consisting of H, -C₁-C₈ alkyl, polyhaloalkyl, -C₃₋₈-cycloalkyl, aryl, alkylaryl, substituted aryl, heteroaryl, and substituted heteroaryl;

15

D is selected from the group consisting of $-NR^1-(C=O)-R^2$, $-O-R^1$;



wherein:

R^1 is independently selected from the group consisting of:

- 5 H, C_1-C_8 alkyl, polyhaloalkyl, $-C_{3-8}$ -cycloalkyl, aryl, alkylaryl, substituted aryl, heteroaryl, substituted heteroaryl, $-(C=O)-C_1-C_8$ alkyl, $-(C=O)$ -aryl, $-(C=O)$ -substituted aryl, $-(C=O)$ -heteroaryl and $-(C=O)$ -substituted heteroaryl;

R^2 is independently selected from the group consisting of: aryl, substituted aryl, heteroaryl, and substituted heteroaryl, or

- 10 R^1 and R^2 can be direct linked or can be indirectly linked through a carbon chain that is from 1 to about 8 carbon atoms in length,

n is an integer from 0-4,

m is an integer from 0 or 1,

y is an integer from 0-4 and

Q is independently C or N, wherein when Q is a ring carbon atom, each ring carbon atom is independently substituted by X, wherein

X is in each case a member independently selected from the group consisting of:

hydrogen, halogen, polyhaloalkyl, $-OR^3$, $-SR^3$, $-CN$, $-NO_2$, $-SO_2R^3$, $-C_{1-10}$ -alkyl,
- C_{3-8} -cycloalkyl, aryl, aryl-substituted by 1-4 R^3 groups, amino, amino- C_{1-8} -alkyl,
 C_{1-3} -acylamino, C_{1-3} -acylamino- C_{1-8} -alkyl, C_{1-6} -alkylamino, C_{1-6} -alkylamino C_{1-8}
alkyl, C_{1-6} dialkylamino, C_{1-6} dialkylamino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy- C_{1-6} -alkyl,
carboxy- C_{1-6} -alkyl, C_{1-3} -alkoxycarbonyl, C_{1-3} -alkoxycarbonyl- C_{1-6} -alkyl,
carboxy C_{1-6} alkyloxy, hydroxy, hydroxy C_{1-6} alkyl, and a 5 to 10 membered
fused or non-fused aromatic or nonaromatic heterocyclic ring system, having 1 to
4 heteroatoms independently selected from N, O, and S, with the proviso that the
carbon and nitrogen atoms, when present in the heterocyclic ring system, are
unsubstituted, mono- or di- substituted independently with 0-2 R^4 groups,

wherein R^3 and R^4 are each independently selected from the group consisting of:

hydrogen, halogen, $-CN$, $-NO_2$, $-C_{1-10}$ alkyl, C_{3-8} -cycloalkyl, aryl,
amino, amino- C_{1-8} -alkyl, C_{1-3} -acylamino, C_{1-3} -acylamino- C_{1-8} -alkyl, C_{1-6} -alkylamino, C_{1-6} -alkylamino C_{1-8} alkyl, C_{1-6}
dialkylamino, C_{1-6} dialkylamino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6}
alkoxy- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-3} -alkoxycarbonyl,
 C_{1-3} -alkoxycarbonyl- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyloxy, hydroxy,
hydroxy- C_{1-6} -alkyl, -thio and thio- C_{1-6} -alkyl;


Y is selected from the group consisting of O, S, $N-OR^5$, and NR^5 .

wherein R^5 is selected from the group consisting of:

H, C_{1-10} alkyl, C_{3-8} -cycloalkyl, NR^2 , and CN; and

Z is selected from the group consisting of NR^1 and O;
or pharmaceutically acceptable salts and prodrugs.


W is selected from the group consisting of:



and


3. A compound according to claim 1, wherein:


D is selected from the group consisting of:





5

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	











4. A compound according to 1, having the following formula:




5. wherein:


R₂ is selected from the group consisting of:



10. R₁ is selected from the group consisting of:




15. W is selected from the group consisting of:



Y is selected from the group consisting of:




A is selected from the group consisting of:



5

[illegible]

5. A compound according to claim 1, having the following formula,








wherein:

n is an integer from 0-4;


X is selected from the group consisting of:

3-Br, 3-Cl, 4-OMe, H, 3-SO₂Me, 3-N(Me)₂ and 3,4,-dimethyl;

10 W is selected from the group consisting of:



and



Y is selected from the group consisting of:

O





, N-C≡N

NH


and



15 A is selected from the group consisting of:




and




20

6. A compound of claim 1, having the following formula:




wherein:


5. Y is selected from the group consisting of:



A is selected from the group consisting of:



7. A compound of claim 1, having the following formula:




5 wherein

R₁ is selected from the group consisting of:

H, Me and 


R₂ is selected from the group consisting of:













W is selected from the group consisting of:



8. A compound of claim 1, selected from the group consisting of:





9. A pharmaceutical composition for preventing or treating thrombosis in a mammal comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5

10. A pharmaceutical composition of claim 9, wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal.

10

11. A pharmaceutical composition of claim 10, wherein said platelet aggregation is platelet ADP-dependent aggregation.

12. A pharmaceutical composition of claim 11, wherein said mammal is a human.

15

13. A pharmaceutical composition of claim 9, wherein said compound is an effective inhibitor of [³H]2-MeS-ADP binding to platelet ADP receptors.

20

14. A pharmaceutical composition for preventing or treating thrombosis in a mammal comprising a therapeutically effective amount of a compound according to claim 8, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition of claim 14, wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal.

25

16. A pharmaceutical composition of claim 15, wherein said platelet aggregation is platelet ADP-dependent aggregation.

17. A pharmaceutical composition of claim 16, wherein said mammal is a human.

30

18. A pharmaceutical composition of claim 14, wherein said compound is an effective inhibitor of [³H]2-MeS-ADP binding to platelet ADP receptors.

19. A method for preventing or treating thrombosis in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

5 20. A method of claim 19, wherein said mammal is a human.

21. A method of claim 19, wherein said mammal is prone to or suffers from a cardiovascular disease.

10 22. A method of claim 19, wherein said cardiovascular disease is at least one selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications
15 following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and prostheses.

20

add
a'